Erlotinib 150mg/day, oral daily
Sponsors
Fukushima Medical University, cancer center
Conditions
non-small cell lung cancer
Phase 2
A phase II study of Erlotinib for patients previously treated non-small cell lung cancer with epidermal growth factor receptor mutation
Active, not recruitingJPRN-UMIN000004563
Start: 2010-03-01Target: 26Updated: 2026-06-29
A phase II study of Erlotinib for elderly patients previously treated non-small cell lung cancer without epidermal growth factor receptor mutation
Active, not recruitingJPRN-UMIN000004561
Start: 2010-03-01Target: 44Updated: 2026-06-29